# Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

> **NCT01920711** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 4822 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** LCZ696
- **DRUG:** Valsartan

## Key facts

- **NCT ID:** NCT01920711
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-18
- **Primary completion:** 2019-06-07
- **Final completion:** 2019-06-07
- **Target enrollment:** 4822 (ACTUAL)
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01920711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01920711, "Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01920711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*